Body composition, glucose metabolism markers and serum androgens - Association in women with polycystic ovary syndrome

Endokrynologia Polska

Volumn 64, Issue 2, 2013, Pages 94-100

  Kozakowski, Jarosław ^a   Zgliczyński, Wojciech ^a  

^a BIELANSKI HOSPITAL   (Poland)

Author keywords

Body composition; Hyperandrogenism; Insulin resistance; Obesity; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; ESTRADIOL; FOLLITROPIN; GLUCOSE; LEPTIN; LIPID; LUTEINIZING HORMONE; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; ANDROGENS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84878134549     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899. (Pubitemid 30647006)
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome Fertil Steril 81: 19-25.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. (Pubitemid 28009567)
4. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83: 1454-1460. (Pubitemid 40615820)
5. Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008; 4: 215-222 (Pubitemid 351430905)
6. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26: 883-896. (Pubitemid 34756169)
7. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 2004; 89: 3694.
8. Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effects of metformin. Human Reprod 2006; 21: 1426-1431. (Pubitemid 44445017)
9. Kravariti M, Naka KK, Kalantaridos SN et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5088-5095. (Pubitemid 41262259)
10. Foltyn W, Strzelczyk J, Marek B et al. Selected markers of endothelial dysfunction in women with polycystic ovary syndrome. Endokrynol Pol 2011; 62: 243-248.
11. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril 2006; 85: 1319-1340.
12. Szydlarska D, Grzesiuk W, Kondracka A et al. Measuring salivary androgens as a useful tool in the diagnosis of polycystic ovary syndrome. Endokrynol Pol 2012; 63: 183-190.
13. Lewandowski KC, Cajdler-Łuba A, Salata I et al. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS). Endokrynol Pol 2011; 62: 120-128.
14. Yildrim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 2003; 79: 1358-1364. (Pubitemid 36687882)
15. Puder JJ, Varga S, Kraenzlin M et al. Central fat excess in polycystic ovary syndrome: relation to low grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-6021. (Pubitemid 41606519)
16. Faloia E, Canibus P, Gatti C et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004; 27: 424-429. (Pubitemid 38961252)
17. Rissanen P, Hamalainen P, Vanninen E et al. Relationship of metabolic variables to abdominal adiposity measured by different anthropometric measurements and dual-energy X-ray absorptiometry in obese middleaged women. Int J Obes Relat Metab Disord 1997; 21: 367-371. (Pubitemid 27190188)
18. Carmina E, Bucchieri S, Esposito A et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extend of its relation to insulin resistance. J Clin Endocrinol Metab 2007; 92: 2500-2505. (Pubitemid 47037349)
19. Radenković SP, Kocić RD, Pešić MM et al. The hypertriglyceridemic waist phenotype and metabolic syndrome by differing criteria in type 2 diabetic patients and their relation to lipids and blood glucose control. Endokrynol Pol 2011; 62: 316-323.
20. Pierpoint T, McKeigue PM, Isaacs AJ et al. Mortality of women with polycystic ovary syndrome at long-term follow up. J Clin Epidemiol 1998; 51: 381-386.
21. Wild S, Pierpoint T, McKeigue P et al. Cardiovascular disease in women with polycystic ovary syndrome at a long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600. (Pubitemid 30337085)
22. Zimmermann S, Phillips RA, Dunaif A et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992; 75: 508-513.
23. Holte J, Gennarelli G, Berne C. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a prehypertensive state? Hum Reprod 1996; 11: 23-28. (Pubitemid 26047667)
24. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. (Pubitemid 28009567)
25. Silfen ME, Denburg MR, Manibo AM et al. Early endocrine, metabolic and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88: 4682-4688. (Pubitemid 37357512)
26. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf). 1994 41: 473-481 (Pubitemid 24301280)
27. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994; 41: 463-471. (Pubitemid 24301279)
28. Godoy-Matos AF, Vaisman F, Pedrosa AP et al. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 793-798.
29. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep 2011; 11: 179-184.
30. Luque-Ramirez M, Alvarez-Blasco F, Escobar-Morreale HF. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients. Obesity 2009; 17: 3-9. (Pubitemid 50324549)
31. Seow KM, Juan CC, Ho LT et al. Adipocyte resistin mRNA levels are down-regulated by laparoscopic ovarian electrocautery in both obese and lean women with polycystic ovary syndrome. Hum Reprod 2007; 22: 1100-1106.
32. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to metabolic syndrome. Endocr Rev 2000; 21: 697-738. (Pubitemid 32113289)